Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 4,234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

NCT00388986
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Glyburide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Honolulu, Hawaii • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 2:39 AM EDT
Terminated Phase 4 Interventional

A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)

NCT01033370
View directory record Official record
Conditions
Aortic Aneurysm, Aortic Disease
Interventions
clevidipine.
Drug
Lead sponsor
Asma Zainab, M.D.
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

A Study of CT-868 in Type 1 Diabetes Mellitus

NCT06062069
View directory record Official record
Conditions
Overweight, Obese, Type 1 Diabetes Mellitus
Interventions
CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo
Drug · Device
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Concord, California • Escondido, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 25, 2026, 2:39 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dronabinol as an Adjunct for Reducing Pain

NCT06454669
View directory record Official record
Conditions
Low Back Pain, Chronic Pain, Back Injuries
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 25, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

NCT07808060
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Eloralintide, Combined oral contraceptive
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 2:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

NCT06726161
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
RYZ811, RYZ801
Diagnostic Test · Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury

NCT05171673
View directory record Official record
Conditions
Soft Tissue Injuries
Interventions
Licart™ (diclofenac epolamine) topical system
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
6 Years to 45 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Little Rock, Arkansas • La Palma, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

NCT03107026
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
dasotraline 4mg, dasotraline 6mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 25, 2026, 2:39 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

NCT04750278
View directory record Official record
Conditions
Severe to Critical COVID 19 With Associated ARDS
Interventions
FP-025 100 mg, FP-025 300 mg, Placebo
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining Lipid Content in Stool After Alpha-cyclodextrin

NCT03002168
View directory record Official record
Conditions
Healthy Participants
Interventions
Alpha-cyclodextrin, Placebo, Triolein radiolabeled with 100 microcuries of 3^Hydrogen, Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Dietary Supplement · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 25, 2026, 2:39 AM EDT
Not listed No phase listed Observational

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

NCT01811290
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Simnad, Virginia, M.D.
Individual
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
65 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
103
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction

NCT02918552
View directory record Official record
Conditions
Heart Failure
Interventions
sodium nitrite, Control
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
70 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 1Phase 2 Interventional

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

NCT04431258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABTL0812, Folfirinox, Placebo
Drug
Lead sponsor
Ability Pharmaceuticals SL
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT05762471
View directory record Official record
Conditions
Overweight or Obesity, Type2 Diabetes Mellitus
Interventions
GSBR-1290, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 25, 2026, 2:39 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07535034
View directory record Official record
Conditions
Gout
Interventions
Dotinurad, Placebo
Drug · Other
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00735371
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 25, 2026, 2:39 AM EDT
Active, not recruiting Phase 3 Interventional

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 2:39 AM EDT
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 25, 2026, 2:39 AM EDT
Not listed Not applicable Interventional

OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study

NCT05405374
View directory record Official record
Conditions
Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Interventions
OSTEOAMP, Infuse
Other · Device
Lead sponsor
Bioventus LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
New Haven, Connecticut • Wichita, Kansas • Paducah, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 25, 2026, 2:39 AM EDT